Safety Reading Notes

Read safety context beside the research guide.

The Noladin ether source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 11259648

PubMed For Dummies Article

Noladin ether Evidence Review: the long-form source walk-through

Quick read
  • Noladin ether currently has 12 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 11259648
  • The evidence classes most visible in the row language are mechanistic or pharmacological (9), insufficient (2), and preclinical (1). PMID 26408156
  • The study-design language most visible in the row language is Animal study (8), Narrative or expert review (2), and Cellular or in vitro study (2). PMID 12432948
  • The repeated topics are noladin ether biology, receptor pharmacology, metabolism, physiology, or safe... (12), which tells the reader where to start opening PubMed and DOI links. PMID 17698254

Start with the research question

Noladin ether is built from 12 source-backed evidence row(s) and 12 research source(s). The current evidence classes read as mechanistic or pharmacological (9), insufficient (2), and preclinical (1), and the study-design language most often reads as Animal study (8), Narrative or expert review (2), and Cellular or in vitro study (2). PMID 11259648

The row-level question is not simply whether Noladin ether is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are noladin ether biology, receptor pharmacology, metabolism, physiology, or safe... (12). PMID 26408156

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 16639008

Preclinical evidence 1 row

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 12787057

Mechanistic evidence 9 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 15901805

Limits and uncertainty 2 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 37085778

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 15148262

Where this page has the most source density

The largest bucket surfaced for this page is noladin ether biology, receptor pharmacology, metabolism, physiology, or safe...: mechanistic or pharmacological. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is noladin ether biology, receptor pharmacology, metabolism, physiology, or safe...: insufficient, which gives readers another way to see what the literature repeatedly circles. PMID 11259648

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 26408156

Bucket chapters: what the literature is circling

noladin ether biology, receptor pharmacology, metabolism, physiology, or safe...: mechanistic or pharmacological

9 research sources 9 rows (1145-1155) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on noladin ether biology, receptor pharmacology, metabolism, physiology, or safe...: mechanistic or pharmacological. It currently draws from 9 research source(s), so the exact study type matters. PMID 11259648

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 11259648

  • Evidence row 1145

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study d... PMID 11259648

  • Evidence row 1155

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study d... PMID 12356827

noladin ether biology, receptor pharmacology, metabolism, physiology, or safe...: insufficient

2 research sources 2 rows (1144, 1146) Evidence class: insufficient

This bucket summarizes source-backed rows focused on noladin ether biology, receptor pharmacology, metabolism, physiology, or safe...: insufficient. It currently draws from 2 research source(s), so the exact study type matters. PMID 26408156

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 26408156

  • Evidence row 1144

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study desig... PMID 26408156

  • Evidence row 1146

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: noladin eth... PMID 12432948

noladin ether biology, receptor pharmacology, metabolism, physiology, or safe...: preclinical

1 research source 1154 Evidence class: preclinical

This bucket summarizes source-backed rows focused on noladin ether biology, receptor pharmacology, metabolism, physiology, or safe...: preclinical. It currently draws from 1 research source(s), so the exact study type matters. PMID 15763177

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 15763177

  • Evidence row 1154

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study... PMID 15763177

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (9 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 11259648

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 26408156

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 22309979
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 15763177
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 12356827

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 11259648

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 26408156

Source-reading checklist for Noladin ether

  1. Open the linked PubMed or DOI record. PMID 11259648
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 26408156
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 12432948
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 17698254
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 16639008

Source Notes

Noladin ether source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 1144

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 26408156

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoids and Their Pharmacological Actions.
  2. Evidence row 1145

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 11259648

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.
  3. Evidence row 1146

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 12432948

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The cannabinoid receptors.
  4. Evidence row 1147

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 17698254

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors.
  5. Evidence row 1148

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 16639008

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility.
  6. Evidence row 1149

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 12787057

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species.
  7. Evidence row 1150

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15901805

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.
  8. Evidence row 1151

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 37085778

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Activation of CB1R alleviates central sensitization by regulating HCN2-pNR2B signaling in a chronic migraine rat model.
  9. Evidence row 1152

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15148262

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.
  10. Evidence row 1153

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 22309979

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats.
  11. Evidence row 1154

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15763177

    Evidence class: preclinical; Study design: Animal study. Source: Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice.
  12. Evidence row 1155

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 12356827

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid.